Market revenue in 2023 | USD 169.4 million |
Market revenue in 2030 | USD 411.0 million |
Growth rate | 13.5% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 33.18% in 2023. Horizon Databook has segmented the Saudi Arabia upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
The Saudi Arabian government and market players are undertaking several initiatives in the biotechnology sector and vaccine development, which is expected to drive the upstream bioprocessing market in the country. For instance, in October 2022, the Ministry of Investment of Saudi Arabia (MISA) and Ginkgo Bioworks, representing the Kingdom of Saudi Arabia, formally entered into a non-binding MoU.
In November 2021, Merck disclosed its commitment to assist SaudiVax Ltd., headquartered in the Kingdom of Saudi Arabia, in establishing an advanced, multi-modality manufacturing facility. The goal is to enable local production of biologics and vaccines tailored for the MENA region.
Positioned as a pioneer, SaudiVax aims to be the first manufacturer and developer of halal vaccines and biotherapeutics in Saudi Arabia, harnessing Merck's integrated CDMO, advanced products, and the application of single-use technologies.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia upstream bioprocessing market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account